Understanding Cancer Before It Becomes Clinically Visible

Most cancers are found too late. Not because the science does not exist to do better, but because the earliest and most important conversation too rarely happens in the right place.

That place is primary care. When a patient sits across from their family doctor, that appointment represents one of the most valuable opportunities in medicine: the chance to ask whether something might be developing before it becomes clinically visible. Early detection does not begin in an oncology clinic. It begins in a GP’s office, a family medicine practice, a routine check-up.

The processes involved in cancer development can start much earlier than the moment a tumour is discovered or a diagnosis is made. Understanding how normal cells evolve and how their behaviour changes over time is an important area of scientific research, offering new opportunities to investigate how cancer develops and how it might be detected sooner.

Researchers are increasingly studying the progression from normal tissue to precancerous conditions and, in some cases, cancer to better understand the biological events that shape this process.

From Normal Tissue to Cancer

Cancer develops through a series of biological changes rather than a single event. Cells may acquire alterations in their DNA, which contains the instructions that guide how cells function, grow and divide. Some of these alterations give cells a growth advantage, allowing them to multiply and form groups of abnormal cells within a tissue.

As additional changes accumulate, cells may begin to behave differently and interact with their surroundings in new ways. In some cases, this progression can lead to precancerous conditions and eventually cancer. However, not every abnormal cell or precancerous condition will develop into cancer, and progression varies depending on the tissue and other biological factors.

These processes are not always detectable through routine clinical examinations or conventional diagnostic methods. This raises an important scientific question: what can researchers learn by studying the stages that precede a cancer diagnosis?

Why Are the Earliest Stages Difficult to Study?

Although researchers have made significant progress in understanding established cancers, the initial stages of cancer development remain less well understood.
One challenge is that these processes may unfold without obvious symptoms or visible abnormalities. By the time a cancer is diagnosed, the tissue may have undergone many additional changes, making it difficult to determine exactly how the disease began and which events contributed to its progression.

Samples from the earliest stages can also be difficult to obtain. Researchers may have limited access to tissue that captures the transition from normal tissue to precancer and early cancer. Studying these processes over time also requires experimental models that accurately reflect what happens in living tissue.
Addressing these challenges could help scientists distinguish biological events that contribute to cancer progression from those that do not.

New Approaches to Understanding Cancer

Advances in research technologies are giving scientists new ways to investigate the earliest stages of cancer. A 2024 review published in Nature Reviews Cancer by Zhou, Tang and Wang highlights several approaches that are helping researchers examine these processes in greater detail.

Organoids and stem-cell-derived models allow researchers to grow organised groups of cells in laboratory conditions. These models can reproduce certain features of human tissues, helping scientists investigate how cancer develops and how cells interact.

Advanced imaging enables researchers to observe cells and tissue structures, providing insights into how abnormalities emerge and evolve. Some techniques allow biological processes to be examined over time.

Single-cell analysis examines individual cells rather than treating an entire tissue sample as one uniform population. This can reveal differences between cells that might otherwise remain hidden when samples are analysed collectively.

Spatial analysis shows where particular cells and molecular features occur within a tissue. Their location can help researchers understand how cells interact with their surrounding environment.

Researchers are also using artificial intelligence (AI) and computational tools to analyse complex biological datasets, identify patterns and investigate relationships that may be difficult to recognise using conventional methods.

Together, these approaches are helping build a more detailed picture of how cancer begins and progresses. They may also help identify biological markers that could inform future detection strategies.

Why Does This Matter for Earlier Detection?

A better understanding of cancer biology could help guide the development of future detection methods. If researchers can identify reliable markers associated with the disease at an earlier stage, these findings may inform approaches for recognising cancer before it becomes clinically apparent.

However, identifying a potential marker is only one part of the process. Researchers must establish whether it reliably indicates developing cancer, whether it can be detected using an appropriate test, and whether acting on the result improves outcomes for patients.

The World Health Organization (WHO) highlights the importance of early cancer diagnosis and appropriate treatment. It also distinguishes early diagnosis, which focuses on identifying cancer in people who have symptoms, from screening, which aims to identify disease in people who do not yet have symptoms.

Both approaches have important roles, but screening methods need to be carefully evaluated to establish that their benefits outweigh potential harms, including false-positive results and unnecessary investigations.

Early Detection Belongs in Primary Care

Understanding the biology of early cancer has implications that extend beyond specialist research settings. It raises a direct question for clinical practice: where should the conversation about early detection begin?

The answer is primary care. Family doctors and general practitioners are typically the first point of contact for patients. They are placed to identify risk, initiate preventive conversations and guide patients towards appropriate screening. Yet early cancer detection has historically been the domain of specialist medicine, often reached only after symptoms appear.

This needs to change. If biological markers can be detected at an early stage using accessible, minimally invasive tools, those tools need to be within the reach of family medicine. The GP’s office is not the end of the clinical pathway. In the context of early detection, it should be the beginning.

From Understanding Biology to Earlier Detection

Advances in experimental models, imaging, molecular analysis and computational tools are expanding our understanding of how cancer develops before it becomes clinically visible. This knowledge is not only advancing laboratory science. It is beginning to inform the development of practical tools that can be used in clinical settings, including primary care.

The challenge is no longer only scientific. It is about ensuring that what the science makes possible reaches patients at the right moment, through the right setting, guided by the clinicians they see first.

The next question is how these insights are already being translated into practical detection approaches, and what it will take to bring early cancer detection into everyday clinical practice.

In our next article, we explore how emerging approaches such as liquid biopsy are being investigated to identify cancer-associated signals in the body, and the opportunities and challenges involved in detecting cancer earlier.

References

1. Zhou R, Tang X, Wang Y. Emerging strategies to investigate the biology of early cancer. Nature Reviews Cancer. 2024. PubMed.
2. World Health Organization. Cancer. WHO cancer overview.